Novartis

Investor type Accelerator
Founders Alexander Clavel Joerg Reinhardt Johann Rudolf

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 52
Average round size
info
The average size of a deal this fund participated in
$86M
Portfolio companies 39
Rounds per year 2.08
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.25
Exits 17
Key employees 46

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

In 1996 was created Novartis, which is appeared as Corporate Investor. The company was established in Europe in Switzerland. The leading representative office of defined Corporate Investor is situated in the Basel.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Novartis, startups are often financed by 5AM Ventures, UPMC, Threshold. The meaningful sponsors for the fund in investment in the same round are MPM Capital, GV, Atlas Venture. In the next rounds fund is usually obtained by GV, Temasek Holdings, Pontifax AgTech.

This organization was formed by Joerg Reinhardt. The overall number of key employees were 44.

The usual things for fund are deals in the range of more than 100 millions dollars. The increased amount of exits for fund were in 2018. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Novartis works on 1 percentage points more the average amount of lead investments. The real fund results show that this Corporate Investor is 11 percentage points less often commits exit comparing to other companies. The fund is constantly included in less than 2 deals per year.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Proteus Digital Health, Cota Healthcare, Caribou Biosciences. We can highlight the next thriving fund investment areas, such as Medical, Therapeutics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Novartis:
Typical Co-investors
Novartis is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Novartis:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Connor Capital SB -
Haibang Capital China, Hangzhou, Zhejiang
iQiyi Sports Beijing, Beijing, China
IT Co -
Jarnac Capital Management -
Jipyong Seoul, Seoul-t'ukpyolsi, South Korea
Madison Capital Partners Chicago, Illinois, United States
Oikocredit International Amersfoort, The Netherlands, Utrecht
Pine Street Capital Partners Massachusetts, United States, Wellesley
TOS TV OITA Japan, Tokyo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Holmusk

Analytics
Biotechnology
Electronic Health Record (EHR)
Health Care
mHealth
Personal Health
Wellness
06 Dec 2021 Singapore, Central, Singapore

Medtech Africa

Health Care
Medical
$20K02 Dec 2021 Ilorin, Kwara, Nigeria

Mekonos Inc.

Biotechnology
Life Science
Nanotechnology
Robotics
Semiconductor
$25M09 Nov 2021 San Francisco, California, United States

XOMA

Biotechnology
Developer Platform
Health Care
Therapeutics
$35M04 Nov 2021 Berkeley, California, United States

Dunad Therapeutics

Biotechnology
Pharmaceutical
$24M02 Nov 2021 London, England, United Kingdom

Aktis Oncology

Biotechnology
Life Science
$72M18 Mar 2021 Boston, Massachusetts, United States

Credence MedSystems

Biopharma
Biotechnology
Health Care
Pharmaceutical
$39M26 Jan 2021 California, United States

Aspen RxHealth

Apps
Health Care
Information Technology
Internet
Medical
Mobile Apps
$23M07 Jan 2021 Tampa, Florida, United States

SomaLogic

Biotechnology
Health Care
Health Diagnostics
Life Science
Medical Device
Pharmaceutical
$81M23 Dec 2020 Boulder, Colorado, United States
News
Flywheel Raises $22M in Series C Funding

– Flywheel announces a $22m Series C funding round.
– The round was led by 8VC and includes iSelect, Argonautic Ventures, Beringea, Novartis, HPE Pathfinder, Spike Ventures, Key Investments, Seraph, Great North Labs and others.
– Flywheel’s cloud-based data management platform enables researchers to accelerate discovery through streamlined data curation and management, automated pipelines for machine learning and analysis, and tools to ensure secure collaboration.
– With Flywheel’s platform in place, researchers across academic, clinical and life sciences organizations can transform productivity and accelerate innovation in imaging research, multicenter studies, AI development and clinical trials.

Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors

– Aktis Oncology completed a $72m Series A financing.
– The round was led by MPM Capital, EcoR1 Capital and Vida Ventures, with participation from Octagon Capital, TCG Crossover, Novartis and Bristol Myers Squibb.
– Aktis Oncology is developing novel alpha radiotherapies to improve upon the efficacy of conventional solid tumor therapies, while limiting toxicity.
– The company has developed proprietary platforms to discover best-in-class tumor targeting agents designed with optimal pharmacology for delivering alpha radiotherapy.
– Aktis Oncology targeting agents are highly tumor penetrant but clear from other areas of the body quickly, to maximize tumor elimination while minimizing potential side effects of treatment.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Novartis?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: